Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open-Label, Placebo-Controlled, Crossover Study
- PMID: 30592549
- PMCID: PMC6510383
- DOI: 10.1111/cts.12609
Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open-Label, Placebo-Controlled, Crossover Study
Abstract
Oral insulin tregopil (IN-105; a new drug under development) may be coadministered with oral antidiabetic drugs, such as metformin in patients with type 2 diabetes mellitus for optimal glycemic control. IN-105 has sodium caprate excipient, a permeation enhancer, for enhancing absorption in the stomach and increasing bioavailability via an oral route. Sodium caprate may increase bioavailability of metformin by a similar mechanism. Therefore, it was necessary to study the effect of IN-105 on pharmacokinetics (PKs) of metformin. In this randomized, open-label, cross-over study, metformin was administered to healthy volunteers receiving IN-105/placebo under fed/fasting conditions. The 90% confidence interval (CI) of the geometric mean ratio of the area under the curve from time zero to infinity (AUC0-inf ; fasting and fed) and peak plasma concentration (Cmax ; fed) of metformin were within 0.80-1.25 acceptance range. Under fasting conditions, the upper bound margin of Cmax was just beyond this range (i.e., 1.27) and was concluded as functionally not relevant. There was no clinically significant effect of sodium caprate/IN-105 on PKs of metformin under fasting/fed conditions, and it was safe.
© 2018 Biocon Research Limited. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Conflict of interest statement
Drs Anand Khedkar and Vinu Jose were employees of Biocon Research Ltd. at the time of study conduct. Dr Harold Lebovitz is a scientific advisor for Biocon, Intarcia Pharmaceuticals, Metacure Ltd., and Poxel Pharmaceuticals. He holds stocks in Abbott, AbbVie, Inc., General Electric, Gilead Sciences, Inc., IBM, Nestlé, and Novartis AG. Dr Alan D. Cherrington is a scientific advisor for Biocon, Fractyl Laboratories, Inc., Metavention, and NuSirt Biopharma, Inc., Sensulin Labs, LLC., These Three Medical, Inc. (T3M), VTV Therapeutics, and Zafgen. He is a consultant at Abvance, Boston Scientific Corporation, California Institute for Biomedical Research (Calibr), Eli Lilly and Company, Galvani Bioelectronics Limited, MedImmune, Novo Nordisk Inc., Silver Lake, Thermalin Diabetes, LLC., Thetis Pharmaceuticals LLC., and VTV Therapeutics. He has received research support from Boston Scientific Corporation, Galvani Bioelectronics Limited, Novo Nordisk, Inc., Silver Lake, and Zafgen, and holds stocks in Fractyl Laboratories, Inc., Metavention, Thetis Pharmaceuticals LLC., and Zafgen and has professional relationships with Abvance, Sensulin Labs, LLC. Dr Alexander Fleming is a board member of Tolerion and Innoneo. He is a consultant at Acasti, Adocia, Biocon, Cardiora, Carthera, Casebia, Diamyd, Diasome, Dance, EnteraBio, Emperra, Fractyl, G‐Medical, Immune Pharma, InsuLine Medical, Intarcia Therapeutics, Intra‐Cellular Therapeutics, InClinica, Ipsen Biopharmaceuticals, Lexicon, Mars Symbioscience, Mediwound, Merck KGaA, Mediwound, Metronom, Mylan, Neovii, NuSirt Biopharma, Orgenesis, Oramed, Permeatus, ProSciento, RenovoRx, Rhythm Pharmaceuticals, Sanofi, Serpin, SkinJect, Suzhou Connect, Thermalin, ThermoFisher, Upkara, Veracyte, VeroScience, Xeris Pharmaceuticals, and Zucara. Dr Sandeep N. Athalye is an employee of Biocon Research Limited and holds stocks in Biocon. Dr Ashwini Vishweswaramurthy is an employee of Biocon Research Limited.
Figures
References
-
- Khedkar, A. et al A dose range finding study of novel oral insulin (IN‐105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes. Metab. 12, 659–664 (2010). - PubMed
-
- Anderberg, E. , Lindmark, T. & Artursson, P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res. 10, 857–864 (1993). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
